Eledon Pharmaceuticals

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cellular transplant, and for people living with autoimmune and neurodegenerative disease. The firm’s compound in development is AT-1501, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential. The CD40L/CD40 pathway is recognized for its prominent role in immune regulation, making it a candidate for therapeutic intervention in transplant tolerance, autoimmune disease, and neuro-inflammation. The company is building upon a deep historical understanding of the CD40/CD40L pathway, as well as preclinical and Phase 1 data, to initiate up to four phase 2 clinical studies with AT-1501. Eledon Pharmaceuticals was founded on March 26, 2004 and is headquartered in Irvine, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

IRVINE, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application to evaluate tegoprubart for the treatment of IgA Nephropathy (IgAN).

Eledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart in IgA Nephropathy

IRVINE, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that senior management will participate in two upcoming investor conferences:

Eledon Pharmaceuticals to Participate in Two Upcoming Investor Conferences

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Paul Little - CFO David-Alexandre Gros - CEO Steve Perrin - President and Chief Scientific Officer Jeff Bornstein - Chief Medical Officer Conference Call Participants Thomas Smith - SVB Securities Rami Katkhuda - LifeSci Capital Operator Greetings, and welcome to Eledon Pharmaceuticals Second Quarter Financial Results Conference Call. At this time all participants are in a listen-only mode.

Eledon Pharmaceuticals, Inc. (ELDN) CEO David-Alexandre Gros on Q2 2022 Results - Earnings Call Transcript

Received FDA clearance of IND application for Phase 2 trial evaluating tegoprubart for the prevention of rejection in kidney transplant recipients

Eledon Pharmaceuticals Reports Second Quarter 2022 Operating and Financial Results

Management to host conference call and webcast at 4:30 pm ET

Eledon Pharmaceuticals to Report Second Quarter 2022 Financial Results on Thursday, August 11, 2022

IRVINE, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune conditions, and neurodegenerative disease, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application to evaluate tegoprubart for the prevention of organ rejection in patients receiving a kidney transplant.

Eledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart for the Prevention of Rejection in Kidney Transplant Recipients

Guardforce AI Co Ltd

Grab Holdings Ltd

Mullen Automotive

Penny stocks to watch this week. The post Penny Stocks To Buy Now?

Penny Stocks To Buy Now? 3 To Watch This Week

IRVINE, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune conditions, and neurodegenerative disease, today announced topline results from a Phase 2a clinical trial of tegoprubart (formerly AT-1501) in patients with amyotrophic lateral sclerosis (ALS).1

Eledon Announces Positive Topline Results from Phase 2a Trial of Tegoprubart Demonstrating Safety, Target Engagement, and Biomarker Response in Patients Living with Amyotrophic Lateral Sclerosis

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Paul Little – Chief Financial Officer David-Alexandre Gros – Chief Executive Officer Steve Perrin – President and Chief Scientific Officer Jeff Bornstein – Chief Medical Officer Conference Call Participants Pete Stavropoulos – Cantor Fitzgerald Nat Charoensook – SVB Matt Kaplan – Ladenburg Thalmann Operator Greetings, and welcome to Eledon Pharmaceuticals First Quarter Financial Results Conference Call. At this time all participants are in a listen-only mode.

Eledon Pharmaceuticals, Inc's (ELDN) CEO David-Alexandre Gros on Q1 2022 Results - Earnings Call Transcript

Topline data for Phase 2a tegoprubart study in amyotrophic lateral sclerosis (ALS) anticipated in June 2022

Eledon Pharmaceuticals Reports First Quarter 2022 Operating and Financial Results

Management to host conference call and webcast at 4:30 p.m. ET Management to host conference call and webcast at 4:30 p.m. ET

Eledon Pharmaceuticals to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022

IRVINE, Calif., April 18, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune conditions, and neurodegenerative disease, today announced that Steve Perrin, Ph.D., President and Chief Scientific Officer, will present at NobleCon18, Noble Capital Markets' Eighteenth Annual Investor Conference on Thursday, April 21st  at 11:30 a.m. ET.

Eledon Pharmaceuticals to Participate in 18th Annual Noble Capital Markets Investor Conference

IRVINE, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune conditions, and neurodegenerative disease, today announced that it will host its first R&D Day on Thursday, April 28, 2022, from 10 a.m. to 12 p.m. ET (7 a.m. to 9 a.m. PT). Members of Eledon's senior management team will be joined by four leading experts for a deep dive on the company's investigational drug, tegoprubart, and the promise of CD40 Ligand targeted immunotherapy for the treatment of amyotrophic lateral sclerosis, kidney transplantation, islet cell transplantation, and IgA nephropathy.

Eledon to Host Virtual R&D Day on Thursday, April 28, 2022

Eledon Pharmaceuticals' (ELDN) CEO David-Alexandre Gros on Q4 2021 Results -Earnings Call Transcript

Topline data from Phase 2a trial of tegoprubart in ALS expected in 2Q 2022

Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Operating and Financial Results

Management to host conference call and webcast at 4:30 pm ET Management to host conference call and webcast at 4:30 pm ET

Eledon Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 24, 2022

IRVINE, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune conditions, and neurodegenerative disease, today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will participate in a fireside chat at the 11th Annual SVB Leerink Virtual Global Healthcare Conference on Thursday, February 17 th at 5:00 p.m. EST.

Eledon Pharmaceuticals to Participate in 11th Annual SVB Leerink Global Healthcare Conference

IRVINE, Calif., Dec. 27, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune conditions, and neurodegenerative disease, today announced that members of management will be participating in two upcoming virtual investor conferences:

Eledon Pharmaceuticals to Participate in January 2022 Investor Conferences

Eledon Pharmaceuticals, Inc. (ELDN) CEO David-Alexandre Gros on Q3 2021 Results - Earnings Call Transcript

Nearing full enrollment in ALS Phase 2 Study; topline data expected 1H 2022

Eledon Pharmaceuticals Reports Third Quarter 2021 Operating and Financial Results

Presentation to focus on potential use of AT-1501 in kidney transplantation as well as research collaboration between Eledon and CareDx to help assess the efficacy of Eledon's investigational AT-1501 for the prevention of rejection in upcoming kidney transplantation trials Presentation to focus on potential use of AT-1501 in kidney transplantation as well as research collaboration between Eledon and CareDx to help assess the efficacy of Eledon's investigational AT-1501 for the prevention of rejection in upcoming kidney transplantation trials

Eledon Pharmaceuticals CEO David-Alexandre C. Gros, M.D.

IRVINE, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), today announced that members of management will be participating in two upcoming virtual investor conferences in November.

Eledon Pharmaceuticals Announces Participation in November Conferences

Eledon Pharmaceuticals to Release Third Quarter Financial Results on Thursday, November 11, 2021

IRVINE, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), announced their participation in the Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS) which is being held virtually on October 7, 2021. Dr. Steve Perrin, Eledon's President and Chief Scientific Officer, will participate in an industry panel roundtable discussing ALS clinical trial design, biomarkers and endpoints. In addition, a poster will be presented on the AT-1501 Phase 2 study in adults with ALS.

Eledon Pharmaceuticals Announces Presentation on AT-1501 at the Virtual 2021 Northeast Amyotrophic Lateral Sclerosis Consortium

IRVINE, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), announced an upcoming presentation on AT-1501, its lead clinical candidate, at the International Pancreas and Islet Transplantation Association (IPITA) Congress, which is being held virtually from October 20-23, 2021.  An oral presentation on the use of AT -1501, and pre-clinical data showing the effectiveness of AT-1501 in preventing islet allograft rejection in nonhuman primate models, will be featured.

Eledon Pharmaceuticals Announces Upcoming Presentation on AT-1501 at the Virtual 2021 International Pancreas and Islet Transplantation Association Congress

News for Eledon Pharmaceuticals Stock (ELDN)